About Reata Pharmaceuticals
Reata Pharmaceuticals is an integrated pharmaceutical company that delivers medicines for deadly and difficult-to-treat diseases. Founded with an understanding of the significant technical risk in developing medicines, the business model was built around small cross functional teams, rapid evaluation of projects for biological activity and clinical viability, quick decision making, and intense analysis of scientific data to determine the direction of individual programs.
Missing: Reata Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Reata Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Reata Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Reata Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Reata Pharmaceuticals Patents
Reata Pharmaceuticals has filed 1 patent.
Polymers, Transcription factors, Monomers, Diabetes, Biological databases
Polymers, Transcription factors, Monomers, Diabetes, Biological databases
Latest Reata Pharmaceuticals News
Nov 28, 2022
2030 | CAGR of 9.5% The Global Ataxia Market Size was valued at USD 30,880.5 Million in 2021 and the worldwide ataxia market is expected to reach USD 69,889.4 Million by 2030. According to a research report published by Spherical Insights & Consulting. Companies Covered: Novartis AG, Merck KgaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata Pharmaceuticals, Inc., MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum Biotechnologies, Inc., Priory, Sutter Health, Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation, ATI Physical Therapy and others 20+ prominent key players we have added in the final report. Global Economy: Recession Risk Rising Analysis November 28, 2022 13:30 ET Pune, INDIA New York, United States , Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Global Ataxia Market Size to grow from USD 30,880.5 million in 2021 to USD 69,889.4 million by 2030, at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period. The ataxia market has grown due to increasing demand for healthcare expenditure and the rising prevalence of ataxia disease. In addition, the government bodies are also approving the market players. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1318 The episodic ataxia segment accounts for the largest market size during the forecast period. Based on the type, the global ataxia market is categorized into Spinocelleblar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA). The episodic ataxia segment accounts for the largest market size during the forecast period. Episodic ataxia is a genetic disorder that can make it hard for someone to walk, move, or keep their balance. These problems happen in separate episodes that can be identified by when they start and end. Episodic ataxia can't be cured, but doctors can help you deal with its symptoms by giving you medicine and putting you through physical therapy. Due to this, the segment is rising. The treatment segment to hold a higher CAGR during the forecast period Based on product, the ataxia market is categorized into Treatment and Diagnosis. The treatment segment to hold higher CAGR during the forecast period. The rise in ataxia disease directly increases the need for treatment among people. And the number of people, especially young people, who drink and do drugs too much is increasing, which makes it more likely that they will suffer from ataxia in the future. Browse key industry insights spread across 190 pages with 241 market data tables and figures & charts from the report “ Global Ataxia Market Size , Share, and COVID-19 Impact Analysis, By Type (Spinocelleblar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA), By Product (Treatment and Diagnosis), By Dosage Form (Solid, Liquids, and Others), By Route of Administration (Oral, Parenteral, and Others), By Patient Type (Adult, Child, and Geriatric), By End User (Hospital, Clinics, Home Healthcare, and Others), By Distribution Channel (Direct Tender, Retail Sales, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Analysis and Forecast 2021 – 2030.” in detail along with the table of contents. Buy Now Full Report: https://www.sphericalinsights.com/checkout/1318 The COVID-19 pandemic has made an adverse impact on credit portfolios. There has been an unprecedented rise in unemployment and disruption in economic activity, putting a strain on the solvency of customers and companies. Central banks have taken a proactive approach by injecting liquidity into the market by lowering interest rates and asset purchase programs. Managing and monitoring credit, market, liquidity, and operational risk across financial markets were hard enough with ongoing geopolitical tensions, international trade wars, and the occasional hurricanes and earthquakes. The current pandemic has forced chief risk officers and their teams to recalibrate old assumptions and models used to manage and monitor risk. COVID-19’s global impact has shown that interconnectedness plays an important role in international cooperation. As a result, many governments started rushing toward identifying, evaluating, and procuring reliable solutions powered by AI. The liquids segment to hold a higher CAGR during the forecast period. Based on dosage form, the ataxia market is categorized into Solid, Liquids, and Others. The liquids segment to hold a higher CAGR during the forecast period. The liquid dosage form is a pharmaceutical preparation made up of parts that are active in the drug and parts that are not active in the drug (excipients). The amount of a substance used as a drug or treatment is meant to be given orally or injected. This dosage form will rapidly dissolve in the body, providing a better therapeutic result. That is why this segment is rising. Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/1318 North America is estimated to account for the highest market share in 2021. The Global Ataxia Market has been segmented into five major regions: Asia-Pacific, Europe, APAC, Latin America, and MEA. As people in these areas have a high rate of ataxia, they now dominate the worldwide ataxia market in terms of market share and market revenue. They are expected to continue to do so during the forecast period. Asia-Pacific to hold a higher CAGR during the forecast period. Some of the Key Developments: In November 2022, Pfizer Inc. said that the Arena Pharmaceuticals purchase had been successfully completed. It is a company that is in the clinical stage of looking for new ways to treat inflammatory and immune-related diseases. With the help of this purchase, the company has been able to add more products to its line. Get Discount At @ https://www.sphericalinsights.com/request-discount/1318 Key Companies & Recent Developments: The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major vendors in the global ataxia market include Novartis AG, Merck KgaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata Pharmaceuticals, Inc., MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum Biotechnologies, Inc., Priory, Sutter Health, Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation, ATI Physical Therapy. Browse Related Reports: Global T-Cell Lymphoma Market Size, Share, and COVID-19 Impact Analysis, By Type of Lymphoma (Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Other Types of Lymphoma), By Type of Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Other Types of Therapies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030.
Reata Pharmaceuticals Web Traffic
Reata Pharmaceuticals Rank
Reata Pharmaceuticals Frequently Asked Questions (FAQ)
When was Reata Pharmaceuticals founded?
Reata Pharmaceuticals was founded in 2002.
Where is Reata Pharmaceuticals's headquarters?
Reata Pharmaceuticals's headquarters is located at 5320 Legacy Dr, Plano.
What is Reata Pharmaceuticals's latest funding round?
Reata Pharmaceuticals's latest funding round is Corporate Minority - P2P.
How much did Reata Pharmaceuticals raise?
Reata Pharmaceuticals raised a total of $463.12M.
Who are the investors of Reata Pharmaceuticals?
Investors of Reata Pharmaceuticals include Blackstone, CPMG, Cardinal Investment Company, Novo Ventures, Novo Holdings and 8 more.
Who are Reata Pharmaceuticals's competitors?
Competitors of Reata Pharmaceuticals include Humanetics, Vaccinex, Bellicum Pharmaceuticals, Bexion Pharmaceuticals, Adastra Pharmaceuticals, OncoMed Pharmaceuticals, Rigel Pharmaceuticals, VentiRx Pharmaceuticals, Neuraltus Pharmaceuticals, Angstrom Pharmaceuticals and 24 more.
Compare Reata Pharmaceuticals to Competitors
NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..
Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.